From the Serviço de Imunologia, Hospital Universitário Clementino Fraga Filho (HUCFF-UFRJ), Rio de Janeiro, Rio de Janeiro, Brasil, Universidade Iguaçu (UNIG), Nova Iguaçu, Rio de Janeiro, Brazil.
Serviço de Imunologia, Hospital Universitário Clementino Fraga Filho (HUCFF-UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil.
Allergy Asthma Proc. 2020 May 1;41(3):e61-e66. doi: 10.2500/aap.2020.41.200003.
The urticaria control test (UCT) is a patient-reported outcome measure designed to determine the current level of disease control in patients with chronic urticaria (CU). Recently, a Brazilian UCT was developed, but its validity and reliability are unknown. The clinimetric properties of the Brazilian UCT short form (UCTsh) and its long form (UCTlg) were determined in 130 patients with CU. In parallel, the urticaria activity scores (UAS) that covers 7 days (UAS7) and 28 days (UAS28) were used to assess disease activity. Subsequently, the results were analyzed statistically to determine the validity, reliability, and interpretability of the Brazilian UCT versions. A total of 107 female (82%) and 23 male patients with CU completed both versions of the Brazilian UCT. Both of the Brazilian UCT versions showed excellent internal consistency reliability. In addition, the Brazilian UCT results showed strong correlations with UAS7 and UAS28 results, which indicated high levels of convergent validity. The test-retest reliability was examined in a subsample of 27 patients with CU and was found to be excellent. Notably, the results of both Brazilian UCT versions correlated extensively, which suggested that the UCTsh can replace the UCTlg without changing the UCT results. The Brazilian UCT is a valid and reliable tool for assessing disease control. To facilitate the use of the Brazilian UCT in global studies and to put a stronger focus on the specificity, we propose that the same cutoff values for well-controlled disease should be used as identified in the original publication of the UCT, i.e., ≥12 points for the UCTsh.
荨麻疹控制测试（UCT）是一种患者报告的结局测量工具，旨在确定慢性荨麻疹（CU）患者当前的疾病控制水平。最近，开发了一种巴西 UCT，但它的有效性和可靠性尚不清楚。在 130 名 CU 患者中，确定了巴西 UCT 短版（UCTsh）和长版（UCTlg）的临床计量学特性。同时，使用涵盖 7 天（UAS7）和 28 天（UAS28）的荨麻疹活动评分（UAS）来评估疾病活动度。随后，对结果进行了统计学分析，以确定巴西 UCT 版本的有效性、可靠性和可解释性。共有 107 名女性（82%）和 23 名男性 CU 患者完成了巴西 UCT 的两个版本。巴西 UCT 的两个版本均表现出极好的内部一致性可靠性。此外，巴西 UCT 的结果与 UAS7 和 UAS28 的结果具有很强的相关性，表明具有高度的收敛有效性。在 27 名 CU 患者的亚样本中检查了测试-重测可靠性，结果发现它非常出色。值得注意的是，巴西 UCT 的两个版本的结果相关性广泛，这表明 UCTsh 可以替代 UCTlg，而不会改变 UCT 的结果。巴西 UCT 是一种有效且可靠的疾病控制评估工具。为了促进巴西 UCT 在全球研究中的使用，并更加注重特异性，我们建议使用与 UCT 原始出版物中确定的相同的疾病控制良好的截断值，即 UCTsh 为≥12 分。
